SURMOUNT ‐ REAL UK : A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity
Obesity · 2026
DOI: 10.1002/oby.70247 ↗Kurz gefasst
Pragmatische Studie in der Zeitschrift Obesity, 2026. Verfasst von Martin K Rutter und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchest…. Hauptthemen laut MEDLINE: Tirzepatide, Obesity, Anti-Obesity Agents. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objective
SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m 2 ) and without diabetes in a UK primary care setting.
Methods
A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through access to participants' integrated electronic healthcare record data. The study will enroll approximately 3000 participants from Greater Manchester, UK, who are randomly assigned in a 1:1 ratio to receive either tirzepatide and SoC or SoC alone.
Results
The primary endpoint is the percent change in body weight from baseline to Month 24, with the time to onset of type 2 diabetes to Month 60 being the key secondary endpoint. Additional endpoints include the impact of tirzepatide versus SoC on obesity‐related complications, health‐related quality of life, healthcare resource utilization, productivity, employment, and sickness‐related absences.
Conclusions
SURMOUNT‐REAL UK employs a novel study design to evaluate real‐world health outcomes and potential long‐term benefits for both participants and the healthcare system associated with the delivery of pharmacological obesity treatment at a population level. The study is intended to generate critical evidence to support informed decision‐making in obesity management, clinical guideline development, and healthcare policy. Trial Registration ClinicalTrials.gov identifier: NCT07247084
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
- Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
- Eli Lilly and Company, Basingstoke, UK.
- NorthWest EHealth (NWEH) Ltd., Manchester, UK.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK.
ORCID-Profile: Naveed Sattar
Förderung
- Eli Lilly and Company
Zitieren
APA
Rutter, M. K., Mount, J., Gibson, J. M., Webb, J., Marler, C., Reed, C., Gore, M., Ye, W., Gomez Valderas, E., Wilding, J., Sattar, N., Davies, M. J., Khunti, K., Haynes, R., & Batterham, R. L. (2026). SURMOUNT ‐ REAL UK : A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity. Obesity. https://doi.org/10.1002/oby.70247
Vancouver
Rutter MK, Mount J, Gibson JM, Webb J, Marler C, Reed C, et al. SURMOUNT ‐ REAL UK : A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity. Obesity. 2026. doi:10.1002/oby.70247
BibTeX
@article{Rutter2026,
author = {Rutter, Martin K and Mount, Julie and Gibson, J Martin and Webb, Joanne and Marler, Cheryl and Reed, Catherine and Gore, Mugdha and Ye, Wenyu and Gomez Valderas, Elisa and Wilding, John and Sattar, Naveed and Davies, Melanie J and Khunti, Kamlesh and Haynes, Richard and Batterham, Rachel L},
title = {SURMOUNT ‐ REAL UK : A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70247}
}
EUVIMED